Payment overview · 2025
General Payments
$2,059.26
59 reported records · 20 companies
Healthcare provider profile · identity verified
Jonathan Scott Cudnik, MD
Allopathic & Osteopathic Physicians|Surgery|Vascular Surgery · MACON, GA · NPI 1285920538
Verified facts
What the public records show
CMS Open Payments records show Jonathan Scott Cudnik, MD received $2,059.26 in general payments during 2025 across 59 reported records.
Endologix LLC accounted for 27.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 39 associated products.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Endologix LLC | Unresolved — no canonical attribution shown | $568.66 | 27.6% | 3 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $561.14 | 27.2% | 21 | 2025 |
| AngioDynamics, Inc. | Unresolved — no canonical attribution shown | $225.16 | 10.9% | 8 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $152.77 | 7.4% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $107.16 | 5.2% | 5 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$77.30 | 3.8% | 4 | 2025 |
| Davol Inc. | Unresolved — no canonical attribution shown | $44.72 | 2.2% | 1 | 2025 |
| W. L. Gore & Associates, Inc. | Unresolved — no canonical attribution shown | $42.41 | 2.1% | 2 | 2025 |
| Smith+Nephew, Inc. | Unresolved — no canonical attribution shown | $41.92 | 2.0% | 1 | 2025 |
| Neuros Medical, Inc. | Unresolved — no canonical attribution shown | $37.58 | 1.8% | 2 | 2025 |
| ConvaTec Inc. | Unresolved — no canonical attribution shown | $32.90 | 1.6% | 1 | 2025 |
| Humacyte Global, Inc. | Unresolved — no canonical attribution shown | $28.56 | 1.4% | 1 | 2025 |
| Inari Medical, Inc. | Unresolved — no canonical attribution shown | $22.42 | 1.1% | 1 | 2025 |
| InspireMD Ltd | Unresolved — no canonical attribution shown | $20.95 | 1.0% | 1 | 2025 |
| Solventum Corporation | Unresolved — no canonical attribution shown | $20.56 | 1.0% | 1 | 2025 |
| LeMaitre Vascular, Inc. | Unresolved — no canonical attribution shown | $19.07 | 0.9% | 1 | 2025 |
| Organogenesis Inc. | Unresolved — no canonical attribution shown | $18.88 | 0.9% | 1 | 2025 |
| Terumo Medical Corporation | Unresolved — no canonical attribution shown | $16.31 | 0.8% | 1 | 2025 |
| Reflow Medical Inc | Unresolved — no canonical attribution shown | $11.04 | 0.5% | 1 | 2025 |
| Sirtex Medical Inc | Unresolved — no canonical attribution shown | $9.75 | 0.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,059.26 | 59 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Alto Abdominal Stent Graft System Normalized: alto abdominal stent graft system |
Device | Endologix LLC | $302.38 | 2 | 2025 |
Source payment records
|
|||||
| AFX2 Bifurcated Endograft System Normalized: afx2 bifurcated endograft system |
Device | Endologix LLC | $266.28 | 1 | 2025 |
Source payment records
|
|||||
| General - Vascular Intervention Normalized: general vascular intervention |
Device | Boston Scientific Corporation | $221.88 | 5 | 2025 |
Source payment records
|
|||||
| AURYON LASER SYSTEM 100-120 VAC Normalized: auryon laser system 100 120 vac |
Device | AngioDynamics, Inc. | $179.10 | 7 | 2025 |
Source payment records
|
|||||
| CLOTTRIEVER BOLD CATHETER Normalized: clottriever bold catheter |
Device | Stryker Corporation | $152.77 | 2 | 2025 |
Source payment records
|
|||||
| ENROUTE Transcarotid Neuroprotection System Normalized: enroute transcarotid neuroprotection system |
Device | Boston Scientific Corporation | $69.01 | 4 | 2025 |
Source payment records
|
|||||
| AngioJet Ultra 5000A Normalized: angiojet ultra 5000a |
Device | Boston Scientific Corporation | $48.04 | 2 | 2025 |
Source payment records
|
|||||
| ALPHAVAC Normalized: alphavac |
Device | AngioDynamics, Inc. | $46.06 | 1 | 2025 |
Source payment records
|
|||||
| ARISTA Normalized: arista |
Device | Davol Inc. | $44.72 | 1 | 2025 |
Source payment records
|
|||||
| Express LD Iliac / Biliary Normalized: express ld iliac biliary |
Device | Boston Scientific Corporation | $43.77 | 2 | 2025 |
Source payment records
|
|||||
| COLLAGENASE SANTYL Normalized: collagenase santyl |
Drug | Smith+Nephew, Inc. | $41.92 | 1 | 2025 |
Source payment records
|
|||||
| Altius Normalized: altius |
Device | Neuros Medical, Inc. | $37.58 | 2 | 2025 |
Source payment records
|
|||||
| IN.PACT ADMIRAL Normalized: in pact admiral |
Device | Medtronic, Inc. | $34.56 | 2 | 2025 |
Source payment records
|
|||||
| JETSTREAM SC Normalized: jetstream sc |
Device | Boston Scientific Corporation | $33.96 | 1 | 2025 |
Source payment records
|
|||||
| AQUACEL AG+ EXTRA Normalized: aquacel ag extra |
Device | ConvaTec Inc. | $32.90 | 1 | 2025 |
Source payment records
|
|||||
| Symvess Normalized: symvess |
Biological | Humacyte Global, Inc. | $28.56 | 1 | 2025 |
Source payment records
|
|||||
| General - Embolics Normalized: general embolics |
Device | Boston Scientific Corporation | $28.15 | 1 | 2025 |
Source payment records
|
|||||
| EXCLUDER Conformable AAA Endoprosthesis with Active Control Normalized: excluder conformable aaa endoprosthesis with active control |
Device | W. L. Gore & Associates, Inc. | $27.43 | 1 | 2025 |
Source payment records
|
|||||
| Innova Vascular Normalized: innova vascular |
Device | Boston Scientific Corporation | $24.62 | 1 | 2025 |
Source payment records
|
|||||
| General - Thrombectomy Normalized: general thrombectomy |
Device | Boston Scientific Corporation | $24.35 | 1 | 2025 |
Source payment records
|
|||||
| PERCLOSE PROSTYLE Normalized: perclose prostyle |
Device | Abbott Laboratories | $24.23 | 1 | 2025 |
Source payment records
|
|||||
| OptiCross 35 Normalized: opticross 35 |
Device | Boston Scientific Corporation | $23.96 | 1 | 2025 |
Source payment records
|
|||||
| ESPRIT Normalized: esprit |
Device | Abbott Laboratories | $23.33 | 1 | 2025 |
Source payment records
|
|||||
| EMBOSHIELD NAV6 Normalized: emboshield nav6 |
Device | Abbott Laboratories | $22.50 | 1 | 2025 |
Source payment records
|
|||||
| CT THROMBECTOMY SYSTEM KIT Normalized: ct thrombectomy system kit |
Device | Inari Medical, Inc. | $22.42 | 1 | 2025 |
Source payment records
|
|||||
| FLOWTRIEVER CATHETER, S Normalized: flowtriever catheter s |
Device | Inari Medical, Inc. | $22.42 | 1 | 2025 |
Source payment records
|
|||||
| VENASEAL Normalized: venaseal |
Device | Medtronic, Inc. | $21.42 | 1 | 2025 |
Source payment records
|
|||||
| CGuard Prime Carotid Stent System Normalized: cguard prime carotid stent system |
Device | InspireMD Ltd | $20.95 | 1 | 2025 |
Source payment records
|
|||||
| V.A.C.ULTA Normalized: v a c ulta |
Device | Solventum Corporation | $20.56 | 1 | 2025 |
Source payment records
|
|||||
| ARMADA Normalized: armada |
Device | Abbott Laboratories | $20.42 | 1 | 2025 |
Source payment records
|
|||||
| ARTEGRAFT VASCULAR GRAFT Normalized: artegraft vascular graft |
Device | LeMaitre Vascular, Inc. | $19.07 | 1 | 2025 |
Source payment records
|
|||||
| NOVACHOR Normalized: novachor |
Medical Supply | Organogenesis Inc. | $18.88 | 1 | 2025 |
Source payment records
|
|||||
| DIAMONDBACK PERIPHERAL Normalized: diamondback peripheral |
Device | Abbott Laboratories | $16.68 | 1 | 2025 |
Source payment records
|
|||||
| ANGIO-SEAL Normalized: angio seal |
Device | Terumo Medical Corporation | $16.31 | 1 | 2025 |
Source payment records
|
|||||
| Charger Normalized: charger |
Device | Boston Scientific Corporation | $15.03 | 1 | 2025 |
Source payment records
|
|||||
| GORE EXCLUDER AAA Endoprosthesis Normalized: gore excluder aaa endoprosthesis |
Device | W. L. Gore & Associates, Inc. | $14.98 | 1 | 2025 |
Source payment records
|
|||||
| General - Atherectomy Normalized: general atherectomy |
Device | Boston Scientific Corporation | $14.41 | 1 | 2025 |
Source payment records
|
|||||
| Epic Vascular Normalized: epic vascular |
Device | Boston Scientific Corporation | $13.96 | 1 | 2025 |
Source payment records
|
|||||
| LAVA LES (Liquid Embolic System) Normalized: lava les liquid embolic system |
Device | Sirtex Medical Inc | $9.75 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Clopidogrel | Clopidogrel Bisulfate | 117 | 52 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 43 | 36 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 14 | suppressed |
| Eliquis | Apixaban | 12 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,059.26 · 59 records | Endologix LLC | AFX2 Bifurcated Endograft System, ALPHAVAC, ANGIO-SEAL, AQUACEL AG+ EXTRA, ARISTA, ARMADA, ARTEGRAFT VASCULAR GRAFT, AURYON LASER SYSTEM 100-120 VAC, Altius, Alto Abdominal Stent Graft System, AngioJet Ultra 5000A, CGuard Prime Carotid Stent System, CLOTTRIEVER BOLD CATHETER, COLLAGENASE SANTYL, CT THROMBECTOMY SYSTEM KIT, Charger, DIAMONDBACK PERIPHERAL, EMBOSHIELD NAV6, ENROUTE Transcarotid Neuroprotection System, ESPRIT, EXCLUDER Conformable AAA Endoprosthesis with Active Control, Epic Vascular, Express LD Iliac / Biliary, FLOWTRIEVER CATHETER, S, GORE EXCLUDER AAA Endoprosthesis, General - Atherectomy, General - Embolics, General - Thrombectomy, General - Vascular Intervention, IN.PACT ADMIRAL, Innova Vascular, JETSTREAM SC, LAVA LES (Liquid Embolic System), NOVACHOR, OptiCross 35, PERCLOSE PROSTYLE, Symvess, V.A.C.ULTA, VENASEAL | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error